Followers | 8 |
Posts | 744 |
Boards Moderated | 0 |
Alias Born | 07/16/2006 |
Monday, January 31, 2011 5:27:42 AM
The CC’s main theme was the introduction of SRDX’s new CEO, Gary Maharaj.
My impression is that Gary will be a pragmatist rather than a visionary. I anticipate that his primary focus will be to increase the use of SRDX’s surface modification intellectual property in medical devices marketed by other companies. In this vein, he mentioned the value of SRDX’s intellectual property with regard to enhancing the minimally invasive qualities of medical devices and reducing infections resulting from medical device use. These are the strengths of the Medical Device Division which I expect to flourish under is his leadership.
I also came away with the impression that Gary will strengthen SRDX’s research and development enterprise and de-emphasize product sales per se. This expectation raises the question: what will happen to the In Vitro Diagnostics division? .... Dan Owczarski asked essentially the same question in the Q&A. Gary responded by stating that certain segments of In Vitro are connected to SRDX’s core competency via formulation and chemistry, and in any event, In Vitro is not hurting the company, but instead providing stability during this transitional period. I took this response to mean that there won’t be any dramatic changes in the In Vitro Diagnostics franchise in the near term... It is worth noting that the growth opportunities referenced in the CC were coming from the In Vitro Diagnostics Division.
====
Selected quotes:
Recent SRDX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 08:06:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 08:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:25:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:24:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:02:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 12:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:00:10 AM
- Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results • Business Wire • 07/31/2024 11:00:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/09/2024 05:49:02 PM
- Form DEFM14A - Definitive proxy statement relating to merger or acquisition • Edgar (US Regulatory) • 07/08/2024 08:28:06 PM
- Kuehn Law Encourages, FFNW, HCP, CALB, and SRDX Investors to Contact Law Firm • PR Newswire (US) • 06/17/2024 12:08:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 06/10/2024 08:57:37 PM
- Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc. • Business Wire • 06/10/2024 11:00:00 AM
- Rowley Law PLLC is Investigating Proposed Acquisition of Surmodics, Inc. • PR Newswire (US) • 05/29/2024 10:36:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/29/2024 12:04:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/29/2024 11:28:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 11:27:01 AM
- Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million • Business Wire • 05/29/2024 11:00:00 AM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/24/2024 08:01:05 PM
- Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance • Business Wire • 05/01/2024 11:00:00 AM
- Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1 • Business Wire • 04/19/2024 11:00:00 AM
- Surmodics to Participate in Upcoming Investor Conferences in March and April • Business Wire • 02/27/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:22:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:18:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:16:12 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM